Aspirin, naproxen, sulindac acid, amino salicylic acid, and celecoxib are NSAIDs that should be considered for use in combination with EZH2 inhibitors for KRAS-driven NSCLC. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.